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Background: Distal pancreatectomy for benign and malignant tumours is the second most common surgical
procedure on the pancreas. Postoperative pancreatic fistulas (POPF) represent the most significant clinical
complication, causing prolongation of hospital stay and the need for additional diagnostic and therapeutic
procedures. Although various techniques for preventing POPF have been evaluated, to date, there is no available
technique that ensures closure of the pancreatic remnant.
Methods/Design: DISCOVER will aim to investigate differences in the postoperative course after a distal
pancreatectomy comparing the standard surgical technique with an alternative technique that provides additional
coverage of the pancreatic remnant by the falciform ligament. The primary endpoint of this trial will be the rate of
POPF. As secondary endpoints, incidence of postoperative morbidity and mortality, length of hospital stay, and
quality of life will be assessed.
DISCOVER is a single-centre, randomised, controlled surgical trial. For statistical analysis, a binary logistic regression
model will be used. With a level of significance of 5% and a power of 80%, a sample size of 75 patients per group
has been identified as necessary.
Discussion: The findings of this trial will help to evaluate the usefulness of the coverage procedure at reducing the
rate of POPF. The results could influence the standard procedure for remnant closure after distal pancreatectomy.
Trial-registration: Clinical trials register (DRKS-ID: DRKS00000546)
Keywords: Coverage procedure, Distal pancreatectomy, Falciform ligament, Pancreatic fistulaBackground
A distal pancreatectomy is generally performed in cases
of benign and malignant tumours of the pancreatic body
or tail. Today, even advanced tumours with infiltration
into neighbouring organs can be resected with good
long-term outcome. Increasing numbers of diagnosed
cystic lesions of the pancreas are a further reason for the
increased need for distal pancreatectomies [1,2]. Despite* Correspondence: jens.werner@med.uni-heidelberg.de
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distribution, and reproduction in any mediumlow mortality rates in high-volume centres, the morbid-
ity of this operation remains high, at up to 64% [3].
The most common morbidity following a distal pancrea-
tectomy is postoperative pancreatic fistula (POPF). Insuffi-
cient healing of the resection margin causes leaking of
aggressive pancreatic fluid into the abdominal cavity. Pas-
sive drainage tubes are routinely placed intra-abdominally
in distal pancreatectomies. If any fluid from the abdominal
cavity shows elevated levels of amylase on or after the
third postoperative day, a POPF has to be assumed ac-
cording to the consensus definition [4]. Most patients with
a POPF are not limited by their physical condition and re-
quire no additional diagnostic or therapeutic steps; thisntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the drainage tubes are removed slowly and in a stepwise
manner during the following days or weeks, most often as
an outpatient treatment. If they are not drained, these
enzyme-rich intra-abdominal fluid collections often in-
duce pain, lack of appetite, and vomiting, resulting in a
prolonged hospital stay. Secondary bacterial infection of
these collections can cause additional septic complica-
tions to varying degrees. Clinically impaired patients
often need further therapeutic interventions such as
nasogastric tubes, parenteral nutrition, antibiotics, and
interventional drainage. Very rarely, angiography or fur-
ther surgery is needed. Depending on the patient’s con-
dition and the therapeutic interventions needed, the
patient may be diagnosed with clinically relevant Grade
B or Grade C POPF (Table 1).
To date, various techniques for closure of the pancreatic
stump have been tried and evaluated, including hand-sewn
suturing, stapler closure, pancreatic duct ligation, ultra-
sonic dissection, pancreatoenteric anastomoses, application
of meshes, and sealing with fibrin glue [3], yet none of
these techniques can ensure a secure closure. New tech-
niques are needed to avoid this complication.
Preliminary data
Ever since distal pancreatectomies were first performed,
there has been a longstanding debate as to the most ef-
fective technique for closure of the pancreatic remnant.
For a long time, several different techniques were prac-
ticed side-by-side without good evidence in favour of or
against any of them [5,6]. In 2005, a systematic review and
meta-analysis verified this lack of evidence. Due to com-
promised comparability because of non-standardised sur-
gical procedures or varying definitions of a POPF, the
rates ranged from 0% up to 60% [7]. The DISPACT trial
compared the two most commonly used techniques
(hand-sewn suturing vs. stapler closure) in a large rando-
mised multicentre trial. In that trial, the detected POPF
rate was 36%, demonstrating that secure primary closure
of the pancreatic resection margin is far from assured with
the current techniques [3].
Recent reports have highlighted the potential advan-
tage of additional coverage of the pancreatic remnantTable 1 Definition and clinical grading of POPF according to
Definition Volume of drainage fluid on or after.
Grade A Clinical condition is good; at most little changes in manag
slow removal of drains.
Grade B Clinical condition is often good; peripancreatic collection m
antibiotics in cases of infection, are often needed. Endosco
drainage. Usually, hospital stay is delayed or readmission is
Grade C Clinical condition is poor and stability may be borderline. M
procedures such as CT-guided drainage, angiography, or rewith autologous serous peritoneal tissue [5,6,8-13]. A pro-
spective series from our institution confirmed that reduced
rates of POPF were associated with shorter hospital stays
and reduced treatment costs [14]. Closure with autologous
patches is not a new technique, but it has long been under-
used. In the 1970s, peritoneal and pleural patches were
used to prevent leakages in anastomoses after oesophageal
and colorectal resections [15,16]. The falciform patch was
initially used in the closure of duodenal and gastric perfo-
rations in high-risk patients [16]. In 2006, its use in the
context of distal pancreatectomies was first described when
skeletonised vessels were wrapped with a falciform patch
to protect them from erosion bleeding due to POPF [17].
Iannitti et al. introduced the use of the falciform patch to
cover pancreatic anastomoses in order to prevent POPF in
pancreaticoduodenectomies and distal pancreatectomies in
a retrospective series [10]. However, the results of recent
studies highlighting this technique in distal pancreatecto-
mies have to be interpreted with caution due to certain
methodological drawbacks including mixed populations,




DISCOVER will aim to compare the effectiveness of add-
itional reinforcement of the pancreatic stump by means of
a coverage technique for preventing a POPF compared to
hand-sewn closure alone in distal pancreatectomies.
The following hypotheses will be tested:
H0: The risk of developing POPF is equal in both
groups.
H1: The risk of developing POPF is different between
the two groups.
Study population and location
The study population for the DISCOVER trial will con-
sist of patients undergoing primary elective open surgery
for benign and malignant tumours, chronic pancreatitis,
or pseudocysts of the pancreatic body or tail. Detailed
eligibility criteria are listed in Table 2.the international study group on pancreatic fistula
ement are needed. Hospital stay is not delayed; condition is managed by
ay occur. Specific forms of therapy, such as parenteral nutrition and
pic stenting of the main pancreatic duct may be necessary for sufficient
required.
ajor changes in clinical management as intensive care and invasive
-operations may be needed.
Table 2 Eligibility criteria
Inclusion criteria Exclusion criteria
● Aged 18 years and over ● Current immunosuppressive
therapy
● Disease of the pancreatic body
or tail or involving this part of
the gland and planned treatment
consisting of elective open distal
pancreatectomy
● Participation in another trial that
might conflict with the
endpoints of this trial
● Pre- or intraoperative sign for
obstruction of the pancreatic
duct in the head of the gland
● Informed consent provided ● Lack of informed consent or
compliance
● Inability to follow the study-
explanations
● Intraoperative: performance
of a distal pancreatectomy
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volume institution with experience in pancreatic surgery
(Department of General, Visceral and Transplantation
Surgery, University Hospital of Heidelberg, Germany).
The clinical study centre of the surgical department
(http://www.klinikum.uni-heidelberg.de/Willkommen.13
0058.0.html) will conduct the DISCOVER trial.Sample size calculation
The sample size calculation is based on the expected
rate of POPF after distal pancreatectomy with and with-
out additional coverage of the pancreatic remnant. The
expected POPF rate of 16% in the experimental group is
based on the results of all available studies [5,6,8-10] in
which coverage of the remnant was performed and the
internationally accepted definition of POPF was used
(according to ISGPF [4]; Table 1). The POPF rate in the
control group is expected to be 36% based on the 30-day
follow-up results of the DISPACT trial in which no
group received additional coverage. With alpha = 5% and
beta = 20%, a sample size of n = 75 per group is neces-
sary to detect a difference between the two groups when
the χ2 test (two-sided analysis) is used. It can be expected
that including covariates of prognostic importance (age,
BMI, and extent of resection) in the logistic regression
model that is applied in confirmatory analysis will increase
the power as compared to that of the χ2 test.Ethics, study registration and consent
Before the start of recruitment, this trial was approved
by the independent ethics committee of the University
of Heidelberg and registered at the German Clinical Trials
Register (DRKS-ID: DRKS00000546). The DISCOVER trial
will be conducted in the context of Good Clinical Practice
and in accordance with the Declaration of Helsinki.
All patients assigned for distal pancreatectomy at the
Department of General, Visceral and Transplantation
Surgery, University of Heidelberg, will be screened foreligibility on the day before the operation. During this
preoperative visit, patients will be informed about the
clinical problem of POPF, the timeline of the DIS-
COVER trial and the possible risks and benefits of par-
ticipation before they will be asked to give their written
informed consent.
Randomisation and the intention-to-treat principle
Patients will be randomised intraoperatively once the
surgical decision to perform a distal pancreatectomy has
been made. Block randomisation was chosen and a ran-
dom list was generated using the PROC PLAN feature
of SAS software™ (Cary, NC, USA). The randomisation
process will be paper-based (using sequentially num-
bered opaque envelopes) and performed by members of
the study centre at our surgical department. If a distal
pancreatectomy will be performed but the randomised
procedure is not fulfilled, the patient will stay in the
allocated group for analysis, according to the intention-
to-treat principle. If the surgical procedure of a distal
pancreatectomy is not accomplished, e.g., because of inop-
erability or the need for total pancreatectomy, the patient
will be excluded from final analysis.
Study treatment
Standardised surgical approach (control group)
The type of abdominal incision (longitudinal or trans-
verse laparotomy) will be determined by the surgeon
performing the procedure. After exploration of the ab-
dominal cavity, the pancreas will be revealed and trans-
sected by scalpel (fish-mouth technique) or by stapler.
The pancreatic duct will be identified and closed by cross-
ing stitches. The dorsal and ventral edges of the resection
margin will be adapted using single stitches. Further ma-
nipulation of the pancreatic remnant such as use of fibrin
glue or reinforcement with meshes will not be allowed.
The decision to perform an additional splenectomy or
cholecystectomy is up to the surgeon’s preference. Fur-
ther abdominal organ resections (e.g., multivisceral re-
section), as well as resection of vessels, do not conflict
with the protocol.
Photodocumentation of the pancreatic stump should
be performed before closure of the abdomen to docu-
ment the type of stump closure. Furthermore, members
of the clinical study centre will make unannounced visits
during operations to observe the surgical closure tech-
nique used on the pancreas.
Just before abdominal wall closure, two passive drain-
age tubes will be placed at the pancreatic remnant for
percutaneous drainage.
Experimental group
In patients randomly assigned to receive the coverage pro-
cedure, the falciform ligament will be separated from the
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to the resection margin of the pancreas and will be fixed
to the ventral and dorsal surfaces of the gland by single
stitches or running suture, to cover the complete closed
margin (Figure 1).
If the falciform ligament cannot be used because of
previous operations or for technical reasons, the gastric
or jejunal wall can be used without opening of the intes-
tinal lumen for the coverage procedure.Safety aspects of the coverage procedure
The falciform ligament and the ligamentum teres hepatis
contained within it, which have no functional purpose in
adults, are sutured to the pancreatic remnant by single
stitches or running suture. A potentially elevated risk of
developing delayed gastric emptying in patients with the
falciform patch, as described in two reports cannot be
excluded [5,8], but no additional complications associ-
ated with this interventional procedure have been de-
scribed in the literature. Following the existing literature,
it is expected that the coverage procedure will not ex-
tend operation time or increase blood loss, although
both of these potential outcomes will be assessed as sec-
ondary endpoints within the trial [8,14].Figure 1 Coverage procedure following distal pancreatectomy. (A) Th
pulled through the minor omentum. (C + D) Subsequently, a dorsal and ve
the ligament to the closed pancreatic stump (ps). vms = vena mesentericaAdverse events and serious adverse events: accessing and
reporting
An adverse event (AE) is any sign or symptom that im-
pairs the patient’s well-being. A serious adverse event
(SAE) is any AE that is life-threatening, prolongs hos-
pital stay, results in persisting disability, or leads to death
during the period of observation. AEs and SAEs will be
recorded by means of daily postoperative ward visits
until discharge and a telephone interview on postopera-
tive day 40, performed by members of the study team
(see below). All AEs of clinical relevance and all SAEs
will be documented in the case report form. The trial in-
vestigator must be informed within 24 hours about SAEs
that occur during hospital stay. The presence of a causal
relationship between AEs or SAEs and the trial interven-
tion will be judged by the investigator.
Postoperative data collection
Daily visits with study patients on all wards will be per-
formed by clinical investigators and study nurses at-
tached to the clinical study centre in order to collect
information on the primary and secondary outcome pa-
rameters and to identify any AEs or SAEs. All surgeons
will have to describe the closure technique that they per-
formed on the pancreas on a standardised form that wille falciform ligament (fl) is separated from the abdominal wall (B) and
ntral suture line (4–0 or 5–0 PDS) is used to fix the serosal surface of
superior; ahc = arteria hepatica communis.
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ation to record whether patients were treated according
to the study protocol and were assigned to their groups
truly at random. After discharge, all medical documents
will be reviewed for assessment of the endpoints.
The DISPACT trial demonstrated an increased rate of
POPF (30% to 36%) between day 7 and day 30 because
this is when re-admission due to the need for further
treatment occurred. To ensure the accurate assessment
of our endpoints, DISCOVER patients will be called by
phone at least 40 days after the operation to record post-
operative development.
All patients will be invited to be seen at the outpatient
clinic (European Pancreas Centre, Department of General,
Visceral and Transplantation Surgery, Heidelberg) three
months after their operation for regular follow-up consist-
ing of oral and physical examination and blood tests. CT
or MR imaging will be performed for regular follow-up,
independent from this trial. The results will be used for
postoperative data collection. Our flowchart summarises
the data collection process with regard to timing and data
type (Table 3).Primary and secondary endpoints
Primary endpoint
The primary endpoint of this trial is the rate of occur-
rence of POPF, as defined by the International Study
Group on Pancreatic Fistula (ISGPF) [4]. A POPF is de-
fined as the abdominal secretion of any measureable vol-
ume with amylase content greater than three times the
upper normal value of serum amylase according to the
centre-specific lab standards. Grading of a POPF mainly
depends on its impact on clinical management. The
need for CT-guided drainage shifts a POPF to Grade C
since this is an invasive procedure (Table 1).Table 3 Flowchart of the DISCOVER trial –course of examinat
Visit 1 2 3




Past and current medical history X
Informed consent X
Physical examination and personal data








Quality of life (EQ-5D questionnaire) X
AE, SAE X X
Drainage parameters (enzyme levels) X
Survival X XSecondary endpoints
Secondary endpoints will be postoperative morbidity
including wound infection, intra-abdominal collection,
delayed gastric emptying [18], postpancreatectomy haem-
orrhage [19], abdominal rupture, operation time, operative
or interventional revisions, in-hospital mortality, duration
of intensive care and hospital stay, need for readmission,
and quality of life before operation, before discharge and
at least 40 days after index operation according to the
EQ-5D questionnaire (www.euroqol.org) (Table 4). The
questionnaire that will be administered 40 days after the
operation will be paper-based and sent to patients by post.
Methods for avoiding bias
Minimizing systemic bias
Block randomisation will be used to ensure that patient
groups are comparable. Randomisation will be performed
by study nurses attached to the clinical study centre at the
Department of Surgery at the University of Heidelberg.
The decision of whether to perform a distal pancreatec-
tomy or a pancreaticoduodenectomy cannot be made
before abdominal exploration has been performed. There-
fore, randomisation will be performed as soon as the deci-
sion on a resection strategy has been achieved by the
surgeon. However, if patients are excluded after random-
isation, e.g., because of a need for total pancreatectomy,
the randomisation number will not be reused.
Minimizing treatment bias
Although the coverage procedure is a technically simple
method and quick to perform, we predict that surgeons
who are unfamiliar with it will experience a learning
curve until they overcome their individual technical dif-
ficulties. At the trial institution, however, the coverage
procedure has been performed since 2009, so all sur-















Table 4 Summary and definitions of secondary outcomes
Outcome parameter Definition
Wound infection Surgical site infection associated with laparotomy that develops during the hospital stay
Intra-abdominal collection Fluid collections in the surgical site with or without signs of infection, usually shown in CT-scans
Delayed gastric emptying (DGE) Inability to tolerate solid food with prolonged need for nasogastric tube for at least four days or
nasogastric re-intubation after POD 3; grading of DGE depends on its impact on clinical course and
management; three grades are used for differentiation [18]
Postpancreatectomy haemorrhage
(PPH)
PPH is classified, according to time of onset (early vs. late), severity (mild vs. severe) and diagnostic and
therapeutic consequences (observation, transfusion, interventional, operative), into three grades [19]
Abdominal rupture Dehiscence of abdominal closure with need for relaparotomy during 40 days after index operation
Operation time Time from skin incision to closure of wound (minutes)
Operative or interventional revisions All actions for diagnostic or therapeutic reasons that are related to an abnormal postoperative course are
documented for analyses.
In-hospital mortality Death of any cause during hospital stay
Need for readmission Readmission to any hospital due to postoperative complications
Quality of life Quality of life, accessed by using the EQ-5D questionnaire (EuroQol Group Foundation)
Hassenpflug et al. Trials 2013, 14:430 Page 6 of 7
http://www.trialsjournal.com/content/14/1/430Minimizing measurement bias
Detection and grading of primary and secondary end-
points will be based on records kept during the hospital
stay. Members of the study team will not be involved in
treatment decisions. Blinding is not needed since occur-
rence of POPF is an objective endpoint that cannot be
influenced by the patient [20]. Blinding of the surgeon is
not feasible.Statistical methods
Analysis
Each patient’s allocation to one of the two analysis popu-
lations will be defined prior to the analysis and will be
documented in the statistical analysis plan. We will dis-
tinguish between the following subpopulations: all pa-
tients who were randomly assigned to one of the groups
will be analysed in the full analysis set according to the
intention-to-treat principle. The per protocol analysis set
will include patients without major protocol deviations,
while in the safety analysis set patients will be analysed
according to treatment rather than randomly. During data
review, deviations from the protocol will be assessed as
“minor” or “major”. Major deviations from the protocol
will lead to the exclusion of the patient from the per
protocol analysis set.Confirmatory analysis
The null hypothesis of the proposed trial assumes that
the rate of POPF type A–C is equal in the two interven-
tion groups. A binary logistic regression model will be ap-
plied in order to compare POPF-rates in the two groups,
adjusting for age, BMI and extent of resection. Confirma-
tory analysis will be based primarily on the full analysisset, which is consistent with the intention-to-treat
principle as it includes all patients as randomised. Missing
values will be replaced by means of the ICA-r method de-
scribed by Higgins et al. [18]. Additionally, sensitivity ana-
lyses will be performed according to alternative methods
for dealing with missing data, such as complete case ana-
lysis. In the final analysis, c_alpha = 0.0087 (alpha = 0.05,
two-sided) will be applied.
Concerning the secondary endpoints, exploratory data
analysis will be performed calculating appropriate sum-
mary measures for the empirical distribution (mean,
standard deviation, median, minimum and maximum for
continuous variables, and frequencies and percentages
for categorical variables) as well as descriptive two-sided
P values. Sensitivity analyses will be conducted for the
perprotocol population as well as for the appropriate
subgroup (e.g., covering methods). The safety analysis
will include calculation and comparison of frequencies
and rates of complications and SAEs. Furthermore, statis-
tical methods will be used to assess the quality of the data
and the homogeneity of the intervention groups. All ana-
lyses will be performed using SAS version 9.1 or higher.Discussion
Distal pancreatectomies are performed for benign or
malignant tumours in most cases. Despite the increasing
caseload, the morbidity associated with this kind of op-
eration remains high, mainly due to POPF, which occur
in up to 60% of patients [7]. Additional diagnostic and
therapeutic procedures are needed for these patients,
leading to prolongation of their hospital stay, readmis-
sion, and an increase of treatment costs [14]. Further-
more, POPF can persist for up to six months. It can be
Hassenpflug et al. Trials 2013, 14:430 Page 7 of 7
http://www.trialsjournal.com/content/14/1/430assumed that quality of life is considerably impaired in
fistula patients.
The DISCOVER trial will evaluate the technique of
additional coverage of the pancreatic remnant and its ef-
fectiveness at reducing the rate of POPF after distal pan-
createctomies. Using the ISGPF-definition of POPF will
enable us to compare our results to those of other trials.
The thesis that quality of life is impaired by POPF will
be tested by means of a validated questionnaire (EQ-5D
questionnaire; EuroQol Group Foundation).
If the use of the coverage procedure can be shown to
reduce the rate of POPF, this would help to establish the
coverage procedure as a standard technique after distal
pancreatectomy.
Trial status
The DISCOVER trial is currently still recruiting. The last
patient is expected to be recruited toward the spring of
2014.
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